Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114786 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Oral Vaccines: A Better Future of Immunization.
Vaccines (Basel)
July 2023
DrD Novel Vaccines Limited, Hong Kong, China.
Oral vaccines are gaining more attention due to their ease of administration, lower invasiveness, generally greater safety, and lower cost than injectable vaccines. This review introduces certified oral vaccines for adenovirus, recombinant protein-based, and transgenic plant-based oral vaccines, and their mechanisms for inducing an immune response. Procedures for regulatory approval and clinical trials of injectable and oral vaccines are also covered.
View Article and Find Full Text PDFRetraction: Sung et al. Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate. 2022, , 2.
Vaccines (Basel)
November 2022
Research Department, DreamTec Cytokines Limited, Hong Kong, China.
The journal retracts the article "Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate"[...
View Article and Find Full Text PDFSafety and Immunogenicity of Inactivated Spores as a Heterologous Antibody Booster for COVID-19 Vaccines.
Vaccines (Basel)
June 2022
Research Department, DreamTec Cytokines Limited, Hong Kong, China.
The coronavirus diseases 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have threatened the world for more than 2 years. Multiple vaccine candidates have been developed and approved for emergency use by specific markets, but multiple doses are required to maintain the antibody level. Preliminary safety and immunogenicity data about an oral dose vaccine candidate using recombinant in healthy adults were reported previously from an investigator-initiated trial in Hong Kong.
View Article and Find Full Text PDFExpression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate.
Vaccines (Basel)
December 2021
Research Department, DreamTec Cytokines Limited, Hong Kong, China.
Various types of vaccines, such as mRNA, adenovirus, and inactivated virus by injection, have been developed to prevent SARS-CoV-2 infection. Although some of them have already been approved under the COVID-19 pandemic, various drawbacks, including severe side effects and the requirement for sub-zero temperature storage, may hinder their applications. () is generally recognized as a safe and endotoxin-free Gram-positive bacterium that has been extensively employed as a host for the expression of recombinant proteins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!